Content deleted Content added
revised wikilink to avoid redirect |
|||
Line 53:
It is structurally similar to [[quinine]], an [[antimalarial]] drug.
It is a [[GLP-1 receptor agonist]] and therefore has potential as a possible treatment for obesity, type 2 diabetes, and [[non-alcoholic fatty liver disease]].<ref>{{cite journal |last1=Xue |first1=Huan |last2=Xing |first2=Hao-Jie |last3=Wang |first3=Bin |last4=Fu |first4=Chao |last5=Zhang |first5=Yu-Shan |last6=Qiao |first6=Xi |last7=Guo |first7=Chao |last8=Zhang |first8=Xiao-Li |last9=Hu |first9=Bin |last10=Zhao |first10=Xin |last11=Deng |first11=Li-Jiao |last12=Zhu |first12=Xiao-Chan |last13=Zhang |first13=Yi |last14=Liu |first14=Yun-Feng |title=Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis |journal=Drug Design, Development and Therapy |date=11 May 2023 |volume=17 |pages=1417–1432 |doi=10.2147/DDDT.S404055 |url=https://www.dovepress.com/cinchonine-a-potential-oral-small-molecule-glucagon-like-peptide-1-rec-peer-reviewed-fulltext-article-DDDT |language=English|doi-access=free }}</ref>
== References ==
| |||